{"title":"Sputum Microbiota Correlates With Metabolome and Clinical Outcomes in Asthma-Bronchiectasis Overlap.","authors":"Xiao-Xian Zhang, Zhen-Feng He, Jia-Hui He, Zhao-Ming Chen, Cui-Xia Pan, Zhen-Hong Lin, Lai-Jian Cen, Hui-Min Li, Yan Huang, Ming-Xin Shi, Wei-Jie Guan","doi":"10.1016/j.arbres.2025.01.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the microbiota and metabolome of patients with ABO compared with bronchiectasis and asthma, and determine the relevance with clinical characteristics, inflammatory endotype and exacerbation risks.</p><p><strong>Methods: </strong>In this prospective cohort study, patients underwent comprehensive assessments, including sputum differential cell count, and sputum collection at baseline. Sputum microbiota was profiled via 16S rRNA gene sequencing and metabolome via liquid chromatography/mass spectrometry. Shannon-Wiener Diversity Index (SWDI) was used to reflect dysbiosis. Patients were followed-up to record exacerbations. ABO patients were stratified by the SWDI and sputum eosinophilia to determine the exacerbation risks.</p><p><strong>Results: </strong>Two hundred forty-seven patients were recruited, including 99 ABO (median age: 53.2 years, 65.7% female), 61 asthma (median age: 39.5 years, 50.8% female) and 87 bronchiectasis patients (median age: 52.3 years, 55.2% female). Both microbiota compositions and metabolites differed among asthma, ABO and bronchiectasis, and between eosinophilic and non-eosinophilic ABO at steady-state. Baseline SWDI of microbiota was highest in asthma, followed by ABO. Both Pseudomonadaceae and Rothia most effectively discriminated ABO from asthma and bronchiectasis. Pseudomonas exhibited a more pronounced negative correlation with other taxa in nonEos-ABO. ABO patients with low SWDI with sputum eosinophilia, or those with high SWDI without sputum eosinophilia, had a shorter time to the first exacerbation. Metabolomic compositions in Eos-ABO separated from nonEos-ABO. The relative abundance of Enterobacteriaceae correlated negatively with 15-hydroxylated eicosatetraenoic acid, whose concentrations were higher in Eos-ABO.</p><p><strong>Conclusions: </strong>Integrating microbiota and metabolome profiles, together with eosinophilic inflammatory endotyping, can inform exacerbation risk and personalized management of ABO.</p>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":" ","pages":""},"PeriodicalIF":8.7000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos De Bronconeumologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.arbres.2025.01.002","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To investigate the microbiota and metabolome of patients with ABO compared with bronchiectasis and asthma, and determine the relevance with clinical characteristics, inflammatory endotype and exacerbation risks.
Methods: In this prospective cohort study, patients underwent comprehensive assessments, including sputum differential cell count, and sputum collection at baseline. Sputum microbiota was profiled via 16S rRNA gene sequencing and metabolome via liquid chromatography/mass spectrometry. Shannon-Wiener Diversity Index (SWDI) was used to reflect dysbiosis. Patients were followed-up to record exacerbations. ABO patients were stratified by the SWDI and sputum eosinophilia to determine the exacerbation risks.
Results: Two hundred forty-seven patients were recruited, including 99 ABO (median age: 53.2 years, 65.7% female), 61 asthma (median age: 39.5 years, 50.8% female) and 87 bronchiectasis patients (median age: 52.3 years, 55.2% female). Both microbiota compositions and metabolites differed among asthma, ABO and bronchiectasis, and between eosinophilic and non-eosinophilic ABO at steady-state. Baseline SWDI of microbiota was highest in asthma, followed by ABO. Both Pseudomonadaceae and Rothia most effectively discriminated ABO from asthma and bronchiectasis. Pseudomonas exhibited a more pronounced negative correlation with other taxa in nonEos-ABO. ABO patients with low SWDI with sputum eosinophilia, or those with high SWDI without sputum eosinophilia, had a shorter time to the first exacerbation. Metabolomic compositions in Eos-ABO separated from nonEos-ABO. The relative abundance of Enterobacteriaceae correlated negatively with 15-hydroxylated eicosatetraenoic acid, whose concentrations were higher in Eos-ABO.
Conclusions: Integrating microbiota and metabolome profiles, together with eosinophilic inflammatory endotyping, can inform exacerbation risk and personalized management of ABO.
期刊介绍：
Archivos de Bronconeumologia is a scientific journal that specializes in publishing prospective original research articles focusing on various aspects of respiratory diseases, including epidemiology, pathophysiology, clinical practice, surgery, and basic investigation. Additionally, the journal features other types of articles such as reviews, editorials, special articles of interest to the society and editorial board, scientific letters, letters to the editor, and clinical images. Published monthly, the journal comprises 12 regular issues along with occasional supplements containing articles from different sections.
All manuscripts submitted to the journal undergo rigorous evaluation by the editors and are subjected to expert peer review. The editorial team, led by the Editor and/or an Associate Editor, manages the peer-review process. Archivos de Bronconeumologia is published monthly in English, facilitating broad dissemination of the latest research findings in the field.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
